View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 7, 2019updated 23 Dec 2019 12:06pm

Chi-Med begins new trial for lymphoma treatment

Hutchison China MediTech (Chi-Med) has commenced a Phase I/Ib clinical trial for the treatment of relapsed or refractory lymphoma patients using its investigational drug candidate HMPL-523.

Hutchison China MediTech (Chi-Med) has commenced a Phase I/Ib clinical trial for the treatment of relapsed or refractory lymphoma patients using its investigational drug candidate HMPL-523.

HMPL-523 is an oral, selective, small-molecule inhibitor of spleen tyrosine kinase, which is known to play a key role in B-cell receptor signalling and is a therapeutic target in different B-cell lymphoma subtypes.

The new international, open-label, two-stage trial will assess the safety, preliminary efficacy and tolerability of the drug candidate in around 80 participants suffering from relapsed or refractory lymphoma.

Chi-Med is conducting the study at multiple sites in the US and Europe. The first patient was dosed last month in the US.

The trial comprises dose escalation and expansion phases and will track primary outcome measures as adverse events determined using the National Cancer Institute Common Terminology Criteria for Adverse Events.

Secondary outcome measures include maximum plasma concentration and area under the concentration-time curve to determine HMPL-523’s pharmacokinetic properties, as well as objective response rate (ORR) for the drug candidate’s anti-tumour activity.

The Phase I/Ib trial is set to be completed in December 2022.

Chi-Med added that the study is designed to support HMPL-523’s Phase Ib dose-expansion programme being conducted across a variety of haematological cancers in Australia and China.

The drug candidate is also being developed for treating immune thrombocytopenia (ITP) in a Phase I trial in China.

Last month, Chi-Med began a separate Phase I/Ib trial for advanced relapsed or refractory lymphoma treatment with its isoform phosphoinositide-3 kinase delta (PI3Kδ) inhibitor, HMPL-689.

This trial will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral HMPL-689 in approximately 85 patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena